CAPR vs. CALT, ETNB, DVAX, OCUL, INVA, PCRX, AMPH, BGM, AUPH, and WVE
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL), Innoviva (INVA), Pacira BioSciences (PCRX), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs.
Capricor Therapeutics (NASDAQ:CAPR) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
Capricor Therapeutics currently has a consensus target price of $35.50, indicating a potential upside of 232.71%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Calliditas Therapeutics AB (publ).
In the previous week, Capricor Therapeutics had 25 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 25 mentions for Capricor Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Capricor Therapeutics' average media sentiment score of 0.54 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.
Capricor Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
Capricor Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Capricor Therapeutics' net margin of -146.86%. Capricor Therapeutics' return on equity of -112.95% beat Calliditas Therapeutics AB (publ)'s return on equity.
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Capricor Therapeutics received 336 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 63.80% of users gave Capricor Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Summary
Capricor Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 5/23/2025 by MarketBeat.com Staff
